Speaker Series – Immunotherapy options in advanced non-small cell lung cancer

This review is a summary of a recent speaker symposia featuring a talk by Professor David Gandara held at MOGA in August.

Professor Gandara outlined the rapidly evolving and challenging landscape of lung cancer management focusing on second-line therapy in patients with advanced non-small cell lung cancer.

Professor Gandara is the principal investigator on an Early Therapeutics award from the National Cancer Institute (NCI), where he leads an interdisciplinary team in developing new anti-cancer agents in a variety of novel drug classes.

Please login below to download this issue (PDF)